MEDIA

Press Releases

Main Menu
Select Year

FDA Accepts BLA Resubmission for DAXI Injections

LEARN MORE

Revance Therapeutics (RVNC) Announces FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines)

LEARN MORE

Revance Receives FDA Acceptance of BLA Resubmission for DaxiboutlinumtoxinA for Glabellar Lines

LEARN MORE

FDA Accepts Revance Application for Its Injection To Treat Frown Lines

LEARN MORE